** Drug developer NKGen Biotech's shares NKGN.O surge 26% to 47 cents
** Company says U.S. FDA has granted "fast track" designation for its experimental drug, troculeucel, for the treatment of moderate Alzheimer's disease, a neurodegenerative disorder that causes cognitive impairment
** The FDA's "fast track" program is designed to facilitate the development and expedite review of drug candidates that aim to treat serious conditions and fulfill an unmet medical need
** NKGN is also developing the drug as a treatment for other neurodegenerative disorders and a broad range of cancers
** Stock fell ~71% in the last 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。